Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …

Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course
characterized by multiple relapses and treatment refractoriness. While recent treatment …

Nuclear export proteins such as exportin-1 (XPO1) transport tumor-suppressor proteins and
other growth-regulatory proteins from the nucleus to the cytoplasm. Overexpression of XPO1 …

Introduction Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in
the challenging landscape of relapsed/refractory multiple myeloma (RRMM). Areas covered …

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple
myeloma (MM) have been made. Nevertheless, patients with MM resistant to …

Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in
the challenging landscape of relapsed/refractory multiple myeloma (RRMM). Areas covered …